Scott Stromatt

Scott Stromatt

Company: GeneTx Biotherapeutics

Job title: Chief Medical Officer

Seminars:

Live Q&A Session with Your Expert Speakers 4:00 pm

Read more

day: Day Two

Developing GTX-102, an Investigational Antisense Oligonucleotide Designed to Target & Inhibit Expression of UBE3A-AS 2:30 pm

Exploring clinical activity and evaluating the safety, tolerability, and plasma and cerebrospinal fluid concentrations of GTX-102 in paediatric patients Discussing the eligibility criteria, dosage and modified trial design chosen in this clinical trial to help inform further clinical trials Investigate the clinical trial outcomes on patients with Angelman’s Syndrome to help inform therapeutic developmentRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.